Gene Therapy Lyfgenia denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Aetna Medical Necessity Denial for Lyfgenia — Why It Happens and How to Appeal

Lyfgenia (lovotibeglogene autotemcel) is an FDA-approved gene therapy for sickle cell disease. A medical necessity denial from Aetna means that the clinical information submitted did not satisfy every requirement in Aetna's Clinical Policy Bulletin (CPB) for this therapy. This is not a determination that the treatment is inappropriate for you — it is a finding that the documentation submitted was insufficient to demonstrate that it is. The distinction matters because it is fully correctable.

## Why Medical Necessity Denials Happen Here

Aetna's CPB for Lyfgenia specifies a set of clinical requirements — typically including confirmed diagnosis, documented disease severity, and prior treatment history with outcomes. Denials occur most often when: records do not explicitly address each criterion; the prescriber's letter is general rather than policy-specific; prior treatment failure is noted but not adequately quantified; or the treating specialist's documentation does not come from a recognized gene therapy program. Each of these gaps can be remedied on appeal.

## Federal Appeal Framework

• Internal appeal: Submit within 180 days of denial. Standard response: 30 days; expedited: 72 hours.
• External review (ACA §2719): After final internal denial, request independent external review — typically within approximately 4 months. The IRO applies clinical standards and is not bound by Aetna's CPB.
• ERISA §503: Employer-sponsored plan members have a federally protected right to full-and-fair review.
• Expedited review: Available if delay poses serious health risk; request in writing.

## Documentation to Gather

1. Confirmed diagnosis records: Genetic and laboratory records confirming sickle cell disease diagnosis, disease subtype, and clinical severity — including frequency and severity of vaso-occlusive events or transfusion requirements, as documented in the chart. 2. Prior treatment history: Dated records for every prior disease-modifying or supportive therapy, with documented clinical response and reason for each change or discontinuation. 3. Specialist medical-necessity letter: Your treating hematologist or gene therapy center physician should write a letter that: (a) explicitly references Aetna's CPB criteria by name; (b) addresses each criterion in turn; and (c) cites specific chart data supporting each requirement. 4. Center qualifications: If Aetna's CPB requires treatment at a specialized or accredited center, include documentation of the treating program's qualifications. 5. FDA prescribing label: Attach to confirm that your case falls within the FDA-approved indication.

## Criteria-Mapping Structure

For each criterion in Aetna's CPB for Lyfgenia, create a table row in your appeal:

| CPB Criterion | Supporting Chart Evidence | Document Source | |---|---|---| | Confirmed sickle cell disease diagnosis | Genetic/lab confirmation | Lab records + specialist note | | Disease severity documentation | Vaso-occlusive event history, transfusion burden | Chart notes, hospitalization records | | Prior therapy tried and outcomes | Treatment history with dates + outcomes | Prescriber letter + pharmacy records | | Prescriber/center qualifications | Treating hematologist credentials; center accreditation | Program documentation |

A medical necessity appeal that directly mirrors the CPB's own language — criterion by criterion — is substantially more likely to succeed than one that only makes a general argument for the treatment's value.